SANOVO
SANOVO asks whether adding savolitinib to first-line osimertinib delays progression in advanced EGFR-mutated, MET-overexpressing NSCLC compared with osimertinib alone. Clinicians in the sources reviewed for this edition differ over readiness for a new standard. They express enthusiasm for upfront dual inhibition while scrutinizing tolerability and survival interpretation. Treatment timing and broader applicability remain open questions in their commentary. SANOVO’s main results are scheduled for ESMO 2026; this reflects commentary before that presentation.
- NCT05009836 ↗
- v1.0.0 · edition 1
- updated Oct 27, 2026
- Focused
7 findings, and what sits behind each
01. Enthusiasm for upfront dual inhibition is not an unconditional endorsement of a new standard
14 statements · 12 passages · 10 sources · 10 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Population and setting, The comparison, Secondary endpoints, Safety and tolerability, Primary endpoint: PFS, Design and conduct.
02. Baseline MET testing raises both a treatment-selection question and a patient-identification burden
8 statements · 9 passages · 9 sources · 8 named voices
Counterview: none recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Population and setting, Primary endpoint: PFS, Secondary endpoints, The comparison, Design and conduct.
03. Tolerability may determine the value of first-line intensification
8 statements · 9 passages · 9 sources · 8 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Safety and tolerability, Secondary endpoints, The comparison, Primary endpoint: PFS, Population and setting, Design and conduct.
04. When to target MET, and against which alternative, remains an open clinical question
9 statements · 8 passages · 8 sources · 8 named voices
Counterview: none recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: The comparison, Population and setting, Secondary endpoints, Safety and tolerability, Design and conduct.
05. Strong survival language needs to remain separate from statistical certainty and endpoint identity
22 statements · 21 passages · 20 sources · 17 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Secondary endpoints, Primary endpoint: PFS, The comparison, Population and setting, Design and conduct, Safety and tolerability.
06. China-specific evidence prompts questions about broader applicability and conditional access
7 statements · 7 passages · 7 sources · 7 named voices
Counterview: none recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Population and setting, Primary endpoint: PFS, Secondary endpoints, The comparison, Safety and tolerability, Design and conduct.
07. Congress prioritization signals interest, while wider amplification carries different meanings
26 statements · 26 passages · 24 sources · 20 named voices
Counterview: none recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Primary endpoint: PFS, Population and setting, Secondary endpoints, The comparison, Safety and tolerability.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 7
Enthusiasm for upfront dual inhibition is not an unconditional endorsement of a new standard
- statements
- 14
- passages
- 12
- sources
- 10
- named voices
- 10
What the statements areViews 9Questions and uncertainty 2Clinical experience 0Comparisons 3Restated results and context 0How passages are usedSupporting a statement 16Giving context 0Recorded with the finding- Counterview: recorded
- Limitations: 2
- Feeds the Medical Affairs question
- 9 posts and articles
- 1 podcast or video
Draws on: Population and setting, The comparison, Secondary endpoints, Safety and tolerability, Primary endpoint: PFS, Design and conduct.
In the full report: the interpretation in full, all 14 statements cited to source and date, and the 10 sources linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full SANOVO report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
Which baseline MET definition and benefit–toxicity evidence would justify upfront dual blockade rather than another first-line strategy or deferred MET targeting?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 100HCP commentary sources screened
- 54sources cited by verified HCP statements
- 20found in screened sources
- 13matched to verified clinician profiles
- 20voices cited in the report
- 78verified statements, each linked to its source
- 23of them from speakers with a confirmed clinical role
- 7findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Focused) is set by the 78 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 78 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 54 | Counts free |
| Speaker attribution for cited voices | 20 | Paid |
Trial aspects
11 discussed · 0 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: PFS | 22 | 23 |
| Secondary endpoints | 20 | 19 |
| Population and setting | 27 | 24 |
| The comparison | 15 | 15 |
| Safety and tolerability | 8 | 9 |
| Design and conduct | 5 | 5 |
| Timing of MET targeting and alternative first-line regimens | 12 | 11 |
| MET assays, thresholds and practical patient identification | 7 | 8 |
| Broader applicability, patient communication and conditional regulatory implications | 6 | 6 |
| Congress prioritization and wider communication framing | 17 | 16 |
| Evidence maturity, statistical interpretation and readiness for practice | 16 | 13 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 88 | 51 | |
| Bluesky threads | 9 | 1 | |
| YouTube | 2 | 2 | |
| Podcasts | 1 | 0 |
max 43 / quarter
- Screened window
- Sep 8, 2021 → Oct 26, 2026
- Cited window
- Sep 8, 2021 → Oct 26, 2026
- Retrieved
- Oct 27, 2026
The trial
from ClinicalTrials.gov- Title
- A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
- Registry
- NCT05009836
- Study IDs
- 2020-504-00CH4
- Sponsor
- Hutchmed
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 412 estimated
- Start
- 2021-09-06 actual
- Primary completion
- 2028-05-30 estimated
- Primary endpoint
- PFS
- Interventions
- 3 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 21 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition do not represent all HCPs or all public discussion; repeated posts and reposts are not independent clinical opinions.
- Some potentially relevant passages were not fully assessed. Unnamed references and differently worded trial references may be missing.
- No trial protocol, exact-trial results publication or matching product-label documents were available, limiting independent assessment of methods, results and regulatory status.
- Several numerical findings are second-hand accounts of conference talks. Their reporting does not establish details that the account itself omits.
- PFS HRs differ between commentators, and the reviewed material does not explain those differences.
- The reviewed statements do not provide a complete safety analysis or establish statistical significance for OS.
- The clinical roles of Alex Ehsan, Adam Januszewski and Minhua Chu are not established in the sources reviewed. The interview identifies Qing Zhou, but independent identity confirmation is unavailable. Several other comments are from unnamed speakers whose identities and clinical roles are unknown.
- The report spans different evidence stages. Earlier requests for full data should not be read as later reactions, and post dates do not prove session dates or changes of mind.
How reports are built and checked: Methods.
Editions and corrections
freeLast checked for new commentary Oct 27, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.
Cite this report
Erudio Health. SANOVO (NCT05009836): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 27, 2026. https://www.erudio.com/reports/sanovo-nct05009836
For your AI agent
The same record as JSON or Markdown, or through the Erudio MCP server
curl https://www.erudio.com/reports/sanovo-nct05009836.json
curl https://www.erudio.com/reports/sanovo-nct05009836.md
# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "sanovo-05009836" })release e06e29d94836f077dbec21a44a6fdb596a27fbf4353eb5a447b895e99ca4a983